Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoviGlobulin in hospitalized adults with severe COVID-19
IRCT20200508047346N1Phase 3Completed
- Sponsor
- Kowsar Biotechnology
- Start
- May 2020
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing CoviGlobulin plus standard of care with Standard of care control (2 arms). Primary endpoints: Clinical improvement within 14 days after admission and Mortality within 14 days. Started May 2020; status: completed.
02
Drugs
CoviGlobulin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200508047346N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200508047346N1.